Cencora Inc (COR) Stock Price, Quote & News

Company Profile

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distr...

Industry: Medical Distribution

Sector: Healthcare

Phone: 610 727 7000

Website: www.cencora.com

Address:

1 West First Avenue, Conshohocken, United States

PrivateProfiteersAnalyst Dec. 25 at 1:34 PM

Actionable Trade Alert for $COR: Market Context: $COR is currently trading at $339.98, showing a neutral RSI of 53.66, indicating no immediate overbought or oversold conditions. The price is below both the 30-day MA of $351.91 and the 50-day MA of $346.87, suggesting potential upward momentum if it breaks these resistance levels. Directional Bias: Given the recent high of $377.54 and low of $296.08 over the last 60 days, the stock has room to grow. The ATR of 5.6 indicates moderate volatility, allowing for potential price movement. Trade Plan: - Suggested Entry: $340.00 - Stop Loss: $325.00 (4.4% risk) - Take Profit Targets: 1. $355.00 (4.4% gain) 2. $370.00 (8.7% gain) 3. $397.00 (16.7% gain) This plan provides a solid risk-reward ratio, with TP3 offering over 17% ROI. Monitor the stock closely for any changes in momentum. https://privateprofiteers.com

0 · Reply

PtolomeusPicks Dec. 24 at 6:23 PM

$COR Future valuation dynamics revolve around strategic clarity amid intensifying competitive pressure, with outcomes shaped by timing and discipline. Execution clarity would stabilize long‑term sentiment.

0 · Reply

ZacksResearch Dec. 24 at 4:37 PM

Wall Street is planting its flag on these 3 medical names for 2026 👀 Analysts are backing $COR, $ADUS and $SEM as long-term winners, pointing to AI adoption, rising home care demand, and facility expansion driving growth across the medical sector. Want to see why these three earned bullish support — and what could fuel their next leg higher? Full breakdown here 👉 https://www.zacks.com/stock/news/2808492/these-3-medical-stocks-have-wall-streets-bullish-vote-for-2026?cid=sm-stocktwits-2-2808492-teaser-26195&ADID=SYND_STOCKTWITS_TWEET_2_2808492_TEASER_26195

0 · Reply

Knowledgeworthmore Dec. 24 at 4:08 PM

$OTLK keep it in the mind theres few fda approved wet amd out there, market is huge only couple company having all the steak, if otlk get approved in the usa, its going to take most of the steak, cause they have very strong partner the $COR and its safer than others.

1 · Reply

ZacksResearch Dec. 24 at 3:37 PM

$COR, $ADUS, $SEM — Why these medical stocks could be among your best bets for 2026, according to analysts! 📈 ✨ Each boasts a Zacks Rank #2 (Buy) and VGM Score of A, with analysts highlighting strong operational strength and growth visibility. These stocks are well-positioned in the evolving healthcare landscape. See what makes them stand out here 👉 https://www.zacks.com/stock/news/2808492/these-3-medical-stocks-have-wall-streets-bullish-vote-for-2026?cid=sm-stocktwits-2-2808492-body-26194&ADID=SYND_STOCKTWITS_TWEET_2_2808492_BODY_26194

0 · Reply

DidYouReadThis Dec. 24 at 2:49 PM

Good luck $OTLK with the 12/31/25 PDUFA! Does 834 views seem low for a network meta-analysis? https://doi.org/10.3390/jmahp13040058 $COR

2 · Reply

OfficialStocktwitsUser Dec. 22 at 3:02 PM

$COR RSI: 38.69, MACD: -2.3099 Vol: 12.94, MA20: 348.52, MA50: 345.68 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

1iquid Dec. 20 at 10:15 AM

OptionWizards Tip (education only): Check if earnings, dividends, or splits are scheduled for COR, REGN, or MNST before opening new option positions. $COR $REGN $MNST Not financial advice.

0 · Reply

ZacksResearch Dec. 19 at 5:28 PM

$COR makes a bold $3.6B bet on oncology — smart move or near-term pain? ⚠️ Cencora’s acquisition of OneOncology deepens its pharma-centric strategy and expands community oncology solutions, strengthening the long-term growth outlook even as it pressures the stock in the short term. Get the full strategic breakdown and risk/reward here 👉 https://www.zacks.com/stock/news/2806884/cencora-to-acquire-oneoncology-to-expand-community-oncology-solutions?cid=sm-stocktwits-2-2806884-teaser-25691&ADID=SYND_STOCKTWITS_TWEET_2_2806884_TEASER_25691

0 · Reply

ZacksResearch Dec. 19 at 4:28 PM

$COR bets big on oncology with a $3.6B OneOncology acquisition! 💼 This strategic move boosts Cencora's specialty solutions, aligning with its pharmaceutical-centric strategy while raising long-term EPS guidance for its U.S. Healthcare Solutions segment to 10-14%. 📈 The deal, valued at a $7.4B enterprise, strengthens COR’s community-based care. Discover the full impact here 👉 https://www.zacks.com/stock/news/2806884/cencora-to-acquire-oneoncology-to-expand-community-oncology-solutions?cid=sm-stocktwits-2-2806884-body-25665&ADID=SYND_STOCKTWITS_TWEET_2_2806884_BODY_25665

0 · Reply

Cencora to take majority control of OneOncology to expand cancer services

Dec 15, 2025, 7:00 AM EST - 10 days ago

Cencora Accelerates OneOncology Acquisition, Extending Solutions Offering for Community Oncology

Dec 3, 2025, 7:30 AM EST - 22 days ago

Cencora Enhances Global Pharmaceutical Logistics Services, Cold Chain Capabilities

Dec 2, 2025, 3:33 PM EST - 22 days ago

Cencora, Inc. (COR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 2, 2025, 12:53 PM EST - 23 days ago

Cencora, Inc. (COR) Presents at Evercore 8th Annual Healthcare Conference Transcript

Nov 7, 2025, 2:05 PM EST - 6 weeks ago

Cencora: Earnings Visibility Driving Re-Rating Potential

Nov 5, 2025, 4:01 PM EST - 7 weeks ago

Cencora, Inc. (COR) Q4 2025 Earnings Call Transcript

Nov 5, 2025, 7:44 AM EST - 7 weeks ago

Cencora to invest $1 billion on US drug distribution, posts upbeat 2026 forecast

Nov 5, 2025, 7:00 AM EST - 7 weeks ago

Drug Distributor Cencora to Invest $1 Billion in U.S. Supply Chain

Nov 5, 2025, 7:00 AM EST - 7 weeks ago

Cencora Announces $1 Billion Investment to Strengthen Its U.S. Distribution Network

Nov 5, 2025, 6:30 AM EST - 7 weeks ago

Cencora Reports Fiscal 2025 Fourth Quarter and Fiscal Year End Results

Nov 1, 2025, 11:15 PM EDT - 7 weeks ago

ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November

ABBV ADP AEP AIZ AOS ATO BDX

Oct 16, 2025, 9:00 AM EDT - 2 months ago

IntrinsiQ Specialty Solutions Expands Data Capabilities to Empower Biopharmaceutical Manufacturers and Physicians with Actionable Insights to Improve Patient Outcomes

Oct 14, 2025, 12:47 PM EDT - 2 months ago

The Market Took a Hit. These 6 Stocks Can Sidestep the Wreckage.

MCK WFC

Oct 6, 2025, 4:30 PM EDT - 2 months ago

Cencora Announces Date and Time for Fourth Quarter Fiscal 2025 Earnings Release

Sep 10, 2025, 2:05 PM EDT - 3 months ago

Cencora, Inc. (COR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 9, 2025, 6:02 PM EDT - 3 months ago

Cencora, Inc. (COR) Presents At Baird Global Healthcare Conference 2025 Transcript

Sep 5, 2025, 11:11 AM EDT - 3 months ago

Cencora, Inc. (COR) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 27, 2025, 4:15 PM EDT - 4 months ago

Cencora Appoints Mark Durcan as Chairman of Its Board of Directors

Aug 12, 2025, 2:31 PM EDT - 4 months ago

Cencora: Yet Another Strong Quarter, But Valuations Still Aren't Cheap

Aug 8, 2025, 5:08 PM EDT - 4 months ago

Cencora Q3: Growing Specialty Drug Distributions, Initiate At Buy

Aug 6, 2025, 12:25 PM EDT - 5 months ago

Cencora, Inc. (COR) Q3 2025 Earnings Call Transcript

Aug 6, 2025, 7:51 AM EDT - 5 months ago

Cencora raises annual profit forecast on strong demand for specialty drugs

Aug 6, 2025, 6:30 AM EDT - 5 months ago

Cencora Reports Fiscal 2025 Third Quarter Results

Jul 3, 2025, 7:30 AM EDT - 6 months ago

Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release

May 28, 2025, 7:30 AM EDT - 7 months ago

Cencora Elects Lori J. Ryerkerk to Its Board of Directors

May 16, 2025, 8:37 AM EDT - 7 months ago

Cencora Continues To Deliver As A Healthcare Distributor With Further Growth Signs

May 7, 2025, 2:06 PM EDT - 8 months ago

Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings

May 7, 2025, 10:55 AM EDT - 8 months ago

Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript

May 7, 2025, 6:30 AM EDT - 8 months ago

Cencora Reports Fiscal 2025 Second Quarter Results

Apr 4, 2025, 3:42 PM EDT - 9 months ago

3 Nearly Trump-Proof Stocks Defying Trump's Tariff Shock

CVS MCK PM

Mar 31, 2025, 7:35 AM EDT - 9 months ago

These 15 stocks are the most profitable companies in the S&P 500

AAPL ABBV AON BA CL CLX DVA

Mar 28, 2025, 7:00 AM EDT - 9 months ago

Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release

Feb 26, 2025, 11:00 AM EST - 10 months ago

Cencora: Higher Potential Returns After Reduced Walgreens Stake

Feb 6, 2025, 8:37 PM EST - 11 months ago

Cencora Announces Common Share Repurchase From Walgreens Boots Alliance

Feb 6, 2025, 8:30 PM EST - 11 months ago

Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds

WBA

Feb 6, 2025, 8:30 AM EST - 11 months ago

Cencora Reinforces Efforts to Strengthen Pharmaceutical Supply Chain with Expansion of Drug Shortages Mitigation Program

Feb 5, 2025, 11:40 AM EST - 11 months ago

Cencora (COR) Q1 2025 Earnings Call Transcript

Feb 5, 2025, 7:23 AM EST - 11 months ago

Cencora raises 2025 profit forecast on specialty drug demand

Feb 5, 2025, 6:30 AM EST - 11 months ago

Cencora Reports Fiscal 2025 First Quarter Results

Jan 27, 2025, 7:30 AM EST - 11 months ago

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

HROW

Jan 13, 2025, 12:07 PM EST - 1 year ago

Using SA's Stock Screener: Sell 6 Overvalued Blue Chips, With Stagnating Growth

COST DHR EL MSGS WST

Jan 8, 2025, 7:30 AM EST - 1 year ago

Cencora Announces Date and Time for First Quarter Fiscal 2025 Earnings Release

Jan 2, 2025, 4:23 PM EST - 1 year ago

Cencora raises annual profit forecast

Jan 2, 2025, 4:15 PM EST - 1 year ago

Cencora Completes Acquisition of Retina Consultants of America

Dec 9, 2024, 4:15 PM EST - 1 year ago

Cencora Closes $1.8 Billion Senior Notes Offering

Dec 6, 2024, 8:30 AM EST - 1 year ago

Cencora Launches Accelerate Pharmacy Solutions to Enhance Support for Hospital and Health System Customers

Dec 5, 2024, 10:26 AM EST - 1 year ago

Cencora: Competitive Advantages Defined

Dec 2, 2024, 10:49 PM EST - 1 year ago

Cencora Prices $500 Million 4.625% Senior Notes Due 2027, $600 Million 4.850% Senior Notes Due 2029 and $700 Million 5.150% Senior Notes Due 2035

Nov 26, 2024, 8:30 AM EST - 1 year ago

Cencora to Host Inaugural Product Showcase

PrivateProfiteersAnalyst Dec. 25 at 1:34 PM

0 · Reply

PtolomeusPicks Dec. 24 at 6:23 PM

0 · Reply

ZacksResearch Dec. 24 at 4:37 PM

0 · Reply

Knowledgeworthmore Dec. 24 at 4:08 PM

1 · Reply

ZacksResearch Dec. 24 at 3:37 PM

0 · Reply

DidYouReadThis Dec. 24 at 2:49 PM

Good luck $OTLK with the 12/31/25 PDUFA! Does 834 views seem low for a network meta-analysis? https://doi.org/10.3390/jmahp13040058 $COR

2 · Reply

OfficialStocktwitsUser Dec. 22 at 3:02 PM

0 · Reply

1iquid Dec. 20 at 10:15 AM

OptionWizards Tip (education only): Check if earnings, dividends, or splits are scheduled for COR, REGN, or MNST before opening new option positions. $COR $REGN $MNST Not financial advice.

0 · Reply

ZacksResearch Dec. 19 at 5:28 PM

0 · Reply

ZacksResearch Dec. 19 at 4:28 PM

0 · Reply

PrivateProfiteersAnalyst Dec. 19 at 3:28 PM

$COR is currently trading at $340.58, with an RSI of 28.39 indicating that it is oversold. The 30-day moving average (MA30) is at $354.88, and the 50-day moving average (MA50) is at $344.98, suggesting a potential upward correction as the price is below both averages. The 60-day high is $377.54, providing a target for potential recovery. Actionable Trade Alert: - Suggested Entry: $340.58 - Stop Loss: $330.00 (below recent support) - Take Profit Targets: 1. $350.00 (1st target, approx. 2.7% ROI) 2. $360.00 (2nd target, approx. 5.7% ROI) 3. $400.00 (3rd target, approx. 17.5% ROI) Market context indicates a potential reversal due to oversold conditions and proximity to key moving averages. The ATR of 7.41 supports this volatility. Implement this trade plan to capitalize on the potential upside. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com

0 · Reply

DidYouReadThis Dec. 18 at 9:30 PM

$REGN $JNJ $COR $OTLK For any pharma stock, what’s your estimate for guessing Europe vs USA earnings? Can you think of any examples that launched in Europe first? For example: guessing US might reach about 80% of Europe earnings, with a 6 month lag?

0 · Reply

prismmarketview Dec. 17 at 5:51 PM

Cencora ( $COR ) is accelerating its roll‑up of oncology services, moving to acquire the majority stake it doesn’t already own in physician‑led OneOncology in a deal that values the platform at $7.4 billion and will transition about $5 billion of cash consideration onto Cencora’s balance sheet. https://prismmarketview.com/cencora-advances-acquisition-of-oneoncology-in-7-4-billion-transaction/

0 · Reply

PrivateProfiteersAnalyst Dec. 17 at 2:15 AM

Actionable Trade Alert for $COR: Market Context: $COR is currently trading at $342.55, with a bearish sentiment indicated by an RSI of 26.24, suggesting oversold conditions. The price is near the 60D low of $289.81, indicating potential for a rebound. Directional Bias: The recent close below the MA30 (355.41) and MA50 (343.71) indicates a bearish trend; however, the oversold RSI suggests a possible reversal. Trade Plan: - Suggested Entry: $342.55 - Stop Loss: $335.00 (below recent support) - Take Profit Targets: 1. $355.00 (1st target, approx. 3.6% gain) 2. $370.00 (2nd target, approx. 8.0% gain) 3. $400.00 (3rd target, approx. 16.8% gain) With the potential for a significant rebound, this trade offers a risk-reward ratio that aligns with our goal of at least 17% ROI on the third target. Stay vigilant and manage risk effectively. https://privateprofiteers.com

0 · Reply

PickAlpha Dec. 15 at 12:32 PM

PickAlpha Morning Report | 2025-12-15 — 5 material moves and analysis • China industrial output falls 4 8 YoY — $FXI, $MCHI • China new home prices drop 2 4 YoY — $FXI, $MCHI • Cencora to buy OneOncology for 7 4B — $COR, $XLV • Etc.. https://open.substack.com/pub/pickalpha/p/pickalpha-morning-report-2025-12-311?r=1m2m41&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

0 · Reply

PickAlpha Dec. 15 at 12:29 PM

PickAlpha Morning Report - Company News: 2025.12.15 News Analysis - 1/2: Cencora to buy majority of OneOncology in $7.4BN enterprise-value deal, pausing buybacks and raising long-term guidance $COR $XLV $IHF $XBI

0 · Reply

PrivateProfiteersAnalyst Dec. 15 at 5:49 AM

Actionable Trade Alert for $COR: Market Context: $COR is currently trading at $346.0, with an RSI of 34.8 indicating it is in oversold territory. The stock is below its 30-day moving average (MA30) of 354.94, suggesting bearish momentum, but it is above the 50-day moving average (MA50) of 342.01, indicating potential support. Directional Bias: The RSI suggests a possible reversal as it approaches oversold conditions, while the proximity to the MA50 may provide a bounce opportunity. The 60-day high of 377.54 and low of 285.83 indicates a significant range, providing room for upward movement. Trade Plan: - Suggested Entry: $346.0 - Stop Loss: $340.0 (below MA50 for protection) - Take Profit Targets: 1. $360.0 (4% gain) 2. $375.0 (8.4% gain) 3. $405.0 (17% gain) This plan targets a minimum 17% ROI on the third take profit. Monitor price action closely for any adjustments. https://privateprofiteers.com

0 · Reply

Knowledgeworthmore Dec. 12 at 3:09 AM

$OTLK when we get approval from FDA and Europe sale are comes positive this thing will fly remember they have partnership with Partnership: Outlook Therapeutics and Syntone Biopharma established a JV in 2020 for the Greater China market (mainland China, Hong Kong, Taiwan, Macau)., and they have world largest partner $COR very excited gl all.

0 · Reply

PrivateProfiteersAnalyst Dec. 11 at 10:42 PM

Actionable Trade Alert for $COR: Market Context: $COR is currently trading at $344.18, showing a bearish sentiment as indicated by an RSI of 36.55, suggesting potential oversold conditions. The price is below both the 30-day MA of 354.77 and the 50-day MA of 341.26, reinforcing a bearish trend. However, the proximity to the 60D Low of 285.76 provides a potential support level. Directional Bias: The RSI indicates that $COR may be due for a rebound, while the recent price action suggests a corrective phase. The ATR of 7.52 indicates moderate volatility, allowing for reasonable target setting. Trade Plan: - Suggested Entry: $344.18 - Stop Loss: $337.66 (below recent support) - Take Profit Targets: 1. $354.77 (30-day MA) - 3% ROI 2. $365.00 (mid-range target) - 6% ROI 3. $404.00 (17% ROI) - targeting a recovery towards the 60D High This plan offers a solid risk-reward ratio, capitalizing on potential upward movement. https://privateprofiteers.com

0 · Reply

Glider549 Dec. 11 at 5:24 AM

$MCK These medical distribution stocks such as $MCK $COR $CAH always rebound and move up every year.

1 · Reply

ZacksResearch Dec. 10 at 2:05 PM

$COR up 50.1% so far this year — what's fueling this pharma powerhouse's growth? 🚀 💼 Strong U.S. Healthcare Solutions segment with 25% operating income growth 🛠️ Strategic RCA acquisition boosting profit margins 📈 Raised FY26 guidance reflecting business outperformance Discover the full growth story here 👉 https://www.zacks.com/stock/news/2802149/heres-why-you-should-add-cencora-stock-to-your-portfolio-now?cid=sm-stocktwits-2-2802149-body-24139&ADID=SYND_STOCKTWITS_TWEET_2_2802149_BODY_24139

0 · Reply

ZacksResearch Dec. 10 at 1:05 PM

Buy alert? This growth story is picking up real steam. $COR’s U.S. Healthcare Solutions strength, RCA gains, and raised FY25 guidance all point to accelerating momentum that’s hard to ignore. Full breakdown here 👉 https://www.zacks.com/stock/news/2802149/heres-why-you-should-add-cencora-stock-to-your-portfolio-now?cid=sm-stocktwits-2-2802149-teaser-24138&ADID=SYND_STOCKTWITS_TWEET_2_2802149_TEASER_24138

0 · Reply

Market Cap	66.07B
Revenue (ttm)	321.33B
Net Income (ttm)	1.55B
EPS (ttm)	N/A
PE Ratio	21.27
Forward PE	19.30
Profit Margin	0.48%
Debt to Equity Ratio	4.38

Volume	381,900
Avg Vol	1,512,820
Day's Range	N/A - N/A
Shares Out	193.99M
Stochastic %K	23%
Beta	0.63
Analysts	Strong Sell
Price Target	$393.60